Table 2

Demographic and clinical characteristics of patients who initiated hepatitis C treatment, %

AllIndia (Punjab State only)IndonesiaMyanmarNigeria (Nasarawa State only)Vietnam
N104 95793 460742420651391869
Sex
 Female30.6%30.6%28.5%47.8%54.7%17.7%
 Male69.4%69.4%71.2%52.3%45.3%82.3%
 Transgender0.02%0.02%0.0%0.0%0.0%0.0%
 Missing0.02%0.0%0.3%0.0%0.0%0.0%
Age
 12–191.3%1.4%0.4%0.1%0.0%0.2%
 20–2924.0%26.4%4.7%3.9%5.8%3.9%
 30–3923.0%22.9%24.8%12.8%13.0%33.2%
 40–4920.9%19.5%32.5%28.4%21.6%36.3%
 50–5915.7%15.4%16.0%31.0%36.7%14.2%
 60–6910.8%10.7%11.8%17.0%14.4%8.4%
 70+4.0%3.7%7.7%6.7%8.6%4.0%
 Missing0.3%0.2%2.2%0.1%0.0%0.0%
Family history of HCV
 Yes0.3%0.1%0.0%9.5%0.7%0.0%
 None reported90.9%99.9%0.0%90.5%99.3%0.0%
 Not available8.9%0.0%100.0%*0.0%0.0%100.0%*
History of injecting drugs
 Yes, reported by patient7.0%5.2%21.1%11.2%0.0%34.5%
 None reported93.0%94.8%78.9%88.8%100.0%65.5%
Known HIV coinfection
 Yes4.9%2.2%22.6%40.2%2.2%33.9%
 None reported95.1%97.8%77.4%59.8%97.8%66.1%
Known HBV coinfection
 Yes0.2%0.0%0.0%3.4%7.2%5.5%
 None reported92.8%100.0%0.0%96.6%92.8%94.5%
 Not available7.1%0.0%100.0%*0.0%0.0%0.0%
HCV genotype
 10.7%0.0%0.0%0.0%1.4%40.0%
 20.02%0.0%0.0%0.0%0.0%1.0%
 30.1%0.0%0.0%0.0%0.0%3.0%
 60.7%0.0%0.0%0.0%0.0%37.0%
 Not available/missing98.6%100.0%*100.0%*100.0%*98.6%19.0%
Cirrhosis
 Compensated8.3%8.1%0.0%17.1%0.0%38.8%
 Decompensated1.0%0.9%0.0%8.7%0.0%2.4%
 Cirrhotic (no additional information)8.9%7.0%38.1%0.0%5.0%0.0%
 Non-cirrhotic81.8%84.0%61.8%74.3%95.0%58.8%
 Missing0.01%0.0%0.1%0.0%0.0%0.0%
Treatment regimen
 SOF/DCV79.0%78.9%78.3%100.0%100.0%62.7%
 SOF/DCV+RBV0.8%0.1%1.3%0.0%0.0%37.3%
 SOF/VEL7.6%8.5%0.0%0.0%0.0%0.0%
 SOF/VEL+RBV11.1%12.5%0.0%0.0%0.0%0.0%
 Other1.5%0.0%20.4%0.0%0.0%0.0%
Treatment duration
 12 weeks88.0%90.4%62.4%67.3%95.0%90.5%
 24 weeks11.8%9.3%37.6%32.7%5.0%9.2%
 Other0.2%0.2%0.0%0.0%0.0%0.3%
Year of treatment initiation
 201618.6%20.9%0.0%0.0%0.7%0.0%
 201722.5%21.2%18.0%80.9%10.8%40.4%
 201819.3%17.9%25.9%19.1%43.2%59.6%
 201922.0%22.3%29.2%0.0%45.3%0.1%
 202011.4%12.4%4.3%0.0%0.0%0.0%
 20216.2%5.2%21.3%0.0%0.0%0.0%
 20220.1%0.0%1.4%0.0%0.0%0.0%
Outcome (N=100 101)†
 Confirmed cured via SVR1264.2%66.5%34.8%79.8%25.9%61.2%
 Failed treatment5.1%5.5%1.2%8.6%2.2%0.4%
 Did not complete treatment9.3%8.6%20.4%1.5%13.7%6.3%
 Completed treatment but did not return for SVR1220.1%18.2%42.0%8.6%58.3%32.0%
 Died1.2%1.2%1.6%1.6%0.0%0.2%
  • *This information was not collected/not available in the database.

  • †A total of 4856 patients did not have adequate follow-up time in the dataset to complete treatment based on date of treatment initiation and date of data collection, and therefore, were excluded from this and all subsequent analyses.

  • DCV, daclatasvir; HBV, hepatitis B virus; HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir; SVR12, sustained virologic response at 12 weeks; VEL, velpatasvir.